25th July 2026, A/Prof Chee L Khoo
We know that 55-65% patients with type 2 diabetes (T2D) have metabolic dysfunction associated fatty liver disease (MAFLD) (1). We also know that 28% of patients with MAFLD will develop T2D if not already present by the time MAFLD is detected (2). There is emerging evidence that there are profound alterations in oral glucose handling in individuals with MAFLD even before T2D is diagnosed.…
12th July 2026, A/Prof Chee L Khoo
We don’t see many acute pancreatitis in our rooms but the incidence of acute pancreatitis is gradually increasing (1). Many will develop further episodes and some will develop chronic pancreatitis. Although most patients with acute pancreatitis have its mild form, some develop moderate or severe acute pancreatitis, both of which include serious complications and an increased risk for death.…
30th June 2026, A/Prof Chee L Khoo
We have waited for a very long time. We only have one second generation long-acting basal insulin even though degludec have been available overseas for ≥ 10 years now. Insulin degludec (iDeg), in combination with a prandial insulin (insulin aspart) has been available in Australia as Ryzodeg® since 2018. But iDeg on its own?…
28th June 2026, A/Prof Chee L Khoo
It’s all over the news. Teplizumab (Tzield) has just been approved by the Australian Therapeutic Goods Administration (TGA) delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus (1). Wow. But what does that mean for our patients already with T1D or those who are at very high risk of developing T1D?…
25th May 2026, A/Prof Chee L Khoo
All of us have more than a few patients with essential hypertension (i.e. hypertension with no secondary causes) who remain hypertensive despite two or three anti-hypertensives. These are patients who are already on an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) plus a calcium channel blocker (CCB) or a diuretic or both.…
10th May 2026, A/Prof Chee L Khoo
We were taught in medical school that meniscal injuries inevitably need arthroscopic debridement. Of course, these are likely the ones that don’t improve with physical therapy – physiotherapy, hydrotherapy or chiropractic treatment. We don’t see those that got better with conservative measures. We also don’t see what happen after they had arthroscopic debridement.…
13th April 2026, NIA Diagnostic Imaging
Lung cancer remains the leading cause of cancer-related mortality in Australia, accounting for over 8,500 deaths each year. The National Lung Cancer Screening Program (NLCSP) is a major step forward, using low-dose CT scans to detect cancer earlier in those at high risk. This initiative is designed to reduce mortality and support better outcomes through early intervention.…
24th February 2026, A/Prof Chee L Khoo
We know that suboptimal glucose control is very associated with the incidence and progression of diabetic retinopathy. The duration of diabetes, high systolic BP, smoking, lack of exercise, poor diet and depression are the other risk factors which increase the incidence of diabetic retinopathy as well as the progression of retinopathy. Sleep disorders, which are commonly observed in people with type 2 diabetes (T2D), are also significant factors that influence the development of diabetic complications [1].…
24th February 2026, A/Prof Chee L Khoo
People on shift work are at higher risk of cardio-metabolic dysfunction including cardiovascular (CV) diseases. People on rotating day and night shifts are even worse because their body has to adapt to a new time clock every couple of weeks. These people include ambulance officers, police officers and hospital doctors! Some of us may not be shift workers but are late owls.…
13th February 2026, NIA Diagnostic Imaging
Trigger finger is a common hand condition that often presents in primary care. It often starts as more an annoyance to the patient but eventually, as it deteriorates, affects the normal functioning of the hand. The only management option used to be surgical release of the tendon. We now have another management option – ultrasound guided cortisone injection.…
12th February 2026, A/Prof Chee L Khoo
When we think about major complications in patients with type 2 diabetes (T2D), we automatically think of an atherosclerotic cardiovascular event. While diabetic kidney disease, diabetic foot disease and retinopathy makes the quality of life miserable the last 5-7 years of their shortened lifespan but it is ASCVD events that kills them.…
28th December 2025, A/Prof Chee L Khoo
We discussed the Lancet Commission’s clinical obesity 12 months ago. Clinical obesity is obesity in the presence of a clinical disease (whether complication or co-morbidity). This is why the PBS is funding semaglutide for patients with obesity and established cardiovascular (CV) disease and not obesity on its own. There are many other “diseases” associated with obesity which will be funded by the PBS in the very near future.…